Revolution Medicines(RVMD) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company ended Q4 2025 with $2.03 billion in cash and investments, and entered into a strategic partnership with Royalty Pharma, providing access to up to $2 billion in committed capital [22][24] - R&D expenses for Q4 2025 were $294.9 million, up from $188.1 million in Q4 2024, primarily due to increased clinical trial and manufacturing expenses [22][23] - G&A expenses for Q4 2025 were $66.7 million, compared to $28.2 million in Q4 2024, driven by commercial preparation activities and personnel-related expenses [23] - The net loss for Q4 2025 was $364.9 million, compared to $194.6 million in Q4 2024, attributed to higher operating expenses [23][24] - Full year 2026 GAAP operating expenses are expected to be between $1.6 billion and $1.7 billion, including estimated non-cash stock-based compensation of $180 million to $200 million [25][26] Business Line Data and Key Metrics Changes - The company has advanced its RAS(ON) inhibitor pipeline, which includes four investigational drugs targeting major oncogenic RAS drivers [8][10] - The most advanced program, daraxonrasib, has shown an unprecedented clinical profile across RAS mutations and is currently being evaluated in three randomized registrational studies in pancreatic cancer [10][11] - Zoldonrasib, a G12D selective inhibitor, has shown a high disease control rate of 95% in initial data from patients with metastatic pancreatic cancer [12][13] Market Data and Key Metrics Changes - The company is focusing on pancreatic cancer, non-small cell lung cancer, and colorectal cancer, with ongoing and planned registrational trials in these areas [14][17] - Approximately 90% of pancreatic cancers are RAS-driven, highlighting the need for RAS-targeted therapies [9] - The company is also exploring collaborations with other firms to evaluate RAS(ON) inhibitors in combination with new targeted therapies [18] Company Strategy and Development Direction - The company aims to revolutionize treatments for patients with RAS-addicted cancers through innovative targeted medicines [7][8] - There is a strong commitment to advancing clinical development programs and preparing for commercialization, particularly in the U.S. market [21][27] - The company is investing in new approaches to overcome RAS-driven drug resistance and extend the clinical benefit of RAS(ON) inhibitors [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of their pipeline to transform treatment standards for difficult-to-treat cancers [27] - The company is well-positioned for substantial impact in 2026, with key milestones across clinical programs and preparations for the first commercial launch [27][28] Other Important Information - The company has received Breakthrough Therapy Designation for daraxonrasib and zoldonrasib, indicating their potential to address significant unmet needs in cancer treatment [10][15] - The company is preparing to initiate a new class of RAS(ON) inhibitors designed to overcome drug resistance [19][20] Q&A Session Summary Question: Plans to advance daraxonrasib combination in first-line non-small cell lung cancer - Management confirmed a high commitment to continue developing daraxonrasib in lung cancer, with ongoing dose optimization and efficacy testing [30][32] Question: Efficacy measure for the second-line PDAC trial - Management indicated that the study is powered for overall survival (OS) and progression-free survival (PFS), but could not provide specific expectations at this time [36][38] Question: Ongoing studies in first-line pancreatic cancer - Management acknowledged excitement around daraxonrasib and discussed the potential impact of its use in first-line studies on OS outcomes [41][42] Question: Collaboration with Bristol's PRMT5 inhibitor - Management explained the rationale for combining RAS inhibitors with multiple PRMT5 inhibitors and emphasized a data-driven approach for advancing into late-stage trials [46][49] Question: RMC-055 and its potential role - Management noted that RMC-055 addresses reactivation of the RAS pathway rather than secondary mutations and will provide more clarity at upcoming scientific meetings [89][90] Question: Commercialization preparations - Management highlighted the progress in launch readiness, with experienced teams in place across various functions and regions [95][96]